FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold
I'm PortAI, I can summarize articles.
Cassava Sciences confirmed that the FDA has placed a full clinical hold on its simufilam epilepsy trial, requiring additional data and protocol modifications. This delay means the trial will not start in the first half of 2026 as planned. The company has $106.1 million in cash reserves, expected to support operations into 2027. Cassava also reported that its Phase 3 Alzheimer's trial for simufilam did not meet key endpoints, leading to discontinuation. Shares fell 25.26% to $2.13.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments